WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Skin Infection Efficacy Framework - v9, Acute Bacterial Skin and Skin Structure Infection Efficacy Endpoints has components Resolution of ABSSSI, Percent Reduction in Lesion Size >= 20 percent measured at -Entry Visit -Specified Time from Entry Visit, Change in Route of Administration documented with Reason for Change in Route of Administration, Improvement in Signs and Symptoms has outcome Failure, Lesion Size derived from Maximum Length, Lesion Response has outcome Success, Improvement in Signs and Symptoms has systemic signs and symptoms -Fever -Elevated WBC -Immature Neutrophils, Lesion Response assessed from Lesion Size, Improvement in Signs and Symptoms has local signs and symptoms -Erythema -Purulent Discharge/Drainage -Non-Purlent Discharge/Drainage -Swelling/Induration -Fluctuance -Tenderness to Palpation -Heat/Localized Warmth -Pain, Failure Reason has option -Inadequate Lesion Size Reduction -LTFU -Death -AE -Non Study Antibiotic, Infection Type has option -Cellulitis/Erysipelas -Major Cutaneous Abscess -Wound Infection, Complications has option -Bacteremia, Resolution of ABSSSI derived from Improvement in Signs and Symptoms, Acute Bacterial Skin and Skin Structure Infection Efficacy Endpoints analyzed with covariates ????, Failure documented with Failure Reason, Percent Reduction in Lesion Size >= 20 percent derived from Lesion Response, Change in Route of Administration documented with Date of Switch IV to Oral, Acute Bacterial Skin and Skin Structure Infection Efficacy Endpoints has components Percent Reduction in Lesion Size >= 20 percent, Indeterminate documented with Indeterminate Reason, Percent Reduction in Lesion Size >= 20 percent measured in population -ITT -microITT -Clinically Evaluable -Microbiologically Evaluable